HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pharmacokinetics of piperacillin during pregnancy.

Abstract
The pharmacokinetics of piperacillin during pregnancy were investigated. Eight pregnant women received 4 g of piperacillin intravenously before caesarean section. Likewise, five non-pregnant subjects of child bearing age received the same dose before a gynaecological operation. The mean peak plasma concentrations of piperacillin were 87.5 and 172.2 mg/L for the pregnant and non-pregnant patients, respectively. The mean umbilical vein concentration was 9.7 mg/L; the mean umbilical artery concentration was 7.4 mg/L and the amniotic fluid concentration 6.8 mg/L. The feto-maternal ratio at the time of caesarean section was 0.27. Pharmacokinetic parameters of piperacillin indicate larger volumes of distribution and higher clearance rates during pregnancy compared with the non-pregnant state. The altered pharmacokinetics of piperacillin during pregnancy suggest that higher doses may be required for effective treatment of serious infections in pregnant women near term.
AuthorsA Heikkilä, R Erkkola
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 28 Issue 3 Pg. 419-23 (Sep 1991) ISSN: 0305-7453 [Print] ENGLAND
PMID1960122 (Publication Type: Journal Article)
Chemical References
  • Piperacillin
Topics
  • Adult
  • Female
  • Half-Life
  • Humans
  • Maternal-Fetal Exchange
  • Piperacillin (pharmacokinetics)
  • Pregnancy (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD